Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

Research output: Contribution to journalArticle

Standard

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. / Astruc, B; Marbach, P; Bouterfa, H; Denot, C; Safari, M; Vitaliti, A; Sheppard, Michael.

In: Journal of Clinical Pharmacology, Vol. 45(7), 01.07.2005, p. 836-844.

Research output: Contribution to journalArticle

Harvard

Astruc, B, Marbach, P, Bouterfa, H, Denot, C, Safari, M, Vitaliti, A & Sheppard, M 2005, 'Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles', Journal of Clinical Pharmacology, vol. 45(7), pp. 836-844.

APA

Vancouver

Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. Journal of Clinical Pharmacology. 2005 Jul 1;45(7):836-844.

Author

Astruc, B ; Marbach, P ; Bouterfa, H ; Denot, C ; Safari, M ; Vitaliti, A ; Sheppard, Michael. / Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. In: Journal of Clinical Pharmacology. 2005 ; Vol. 45(7). pp. 836-844.

Bibtex

@article{943780f72a5d4d82a1275974636da18a,
title = "Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles",
abstract = "Single-dose pharmacokinetic (PK) profiles and multiple-dose PK modeling were compared for long-acting octreotide (20 or 60 mg) and prolonged-release lanreotide (90 or 120 mg) over 91 days; steady-state profiles were simulated. All treatments were well tolerated. Octreotide 20-mg profile showed increased concentration on clay 1, lag from days 2 to 6, then prolonged plateau phase (days 11-41); 60-mg PK was dose proportionol. Lonreotide 90-mg profile showed C-max on day 1 then elimination (apparent t(1/2) 25.5 days); 120-mg profile was underproportional. Steady-state PK of octreotide 20 mg/28 d suggested a C-mean of 1216 pg/mL (range, 1065-1585) with low fluctuation index (43%). Steady-state PK of lanreotide 90 mgl 28 d suggested a C-mean of 4455 pglmL (range, 2499-9279) with high fluctuation index (152%). Long-acting octreotide had more predictable PK than prolonged-release lanreotide. Simulated steady-state profiles suggest long-acting octreotide could be optimized to meet individual patient needs. In contrast, proloned-release lanreotide requires exposure canstantly above the therapeutic target to enable monthly long-term therapy.",
author = "B Astruc and P Marbach and H Bouterfa and C Denot and M Safari and A Vitaliti and Michael Sheppard",
year = "2005",
month = jul,
day = "1",
language = "English",
volume = "45(7)",
pages = "836--844",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

AU - Astruc, B

AU - Marbach, P

AU - Bouterfa, H

AU - Denot, C

AU - Safari, M

AU - Vitaliti, A

AU - Sheppard, Michael

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Single-dose pharmacokinetic (PK) profiles and multiple-dose PK modeling were compared for long-acting octreotide (20 or 60 mg) and prolonged-release lanreotide (90 or 120 mg) over 91 days; steady-state profiles were simulated. All treatments were well tolerated. Octreotide 20-mg profile showed increased concentration on clay 1, lag from days 2 to 6, then prolonged plateau phase (days 11-41); 60-mg PK was dose proportionol. Lonreotide 90-mg profile showed C-max on day 1 then elimination (apparent t(1/2) 25.5 days); 120-mg profile was underproportional. Steady-state PK of octreotide 20 mg/28 d suggested a C-mean of 1216 pg/mL (range, 1065-1585) with low fluctuation index (43%). Steady-state PK of lanreotide 90 mgl 28 d suggested a C-mean of 4455 pglmL (range, 2499-9279) with high fluctuation index (152%). Long-acting octreotide had more predictable PK than prolonged-release lanreotide. Simulated steady-state profiles suggest long-acting octreotide could be optimized to meet individual patient needs. In contrast, proloned-release lanreotide requires exposure canstantly above the therapeutic target to enable monthly long-term therapy.

AB - Single-dose pharmacokinetic (PK) profiles and multiple-dose PK modeling were compared for long-acting octreotide (20 or 60 mg) and prolonged-release lanreotide (90 or 120 mg) over 91 days; steady-state profiles were simulated. All treatments were well tolerated. Octreotide 20-mg profile showed increased concentration on clay 1, lag from days 2 to 6, then prolonged plateau phase (days 11-41); 60-mg PK was dose proportionol. Lonreotide 90-mg profile showed C-max on day 1 then elimination (apparent t(1/2) 25.5 days); 120-mg profile was underproportional. Steady-state PK of octreotide 20 mg/28 d suggested a C-mean of 1216 pg/mL (range, 1065-1585) with low fluctuation index (43%). Steady-state PK of lanreotide 90 mgl 28 d suggested a C-mean of 4455 pglmL (range, 2499-9279) with high fluctuation index (152%). Long-acting octreotide had more predictable PK than prolonged-release lanreotide. Simulated steady-state profiles suggest long-acting octreotide could be optimized to meet individual patient needs. In contrast, proloned-release lanreotide requires exposure canstantly above the therapeutic target to enable monthly long-term therapy.

M3 - Article

C2 - 15951474

VL - 45(7)

SP - 836

EP - 844

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -